Cargando...
Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase
Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton’s tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In preclinical studies, ibrutinib bound to Bruton’s tyrosine kinase with high affinity, leading to inhibition...
Guardado en:
| Publicado en: | Future Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4632638/ https://ncbi.nlm.nih.gov/pubmed/24941982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.51 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|